The company has a robust pipeline with pending FDA approvals and is optimistic about its compounding business. In summary, Hikma Pharmaceuticals has delivered a strong financial performance in 2023 and is positioning itself for continued growth in 2024. So as far as the compounding, the FDA estimates the compounding business is between $2 billion to $3 billion. And this is where you have more clarity on the performance of the injectable and the performance of the compounding business. The plans is to get it separated into others and then you will be able to see the performance of the compounding business going forward.

Source: The North Africa Journal February 24, 2024 11:50 UTC